Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate.
Hemorrhagic cystitis (HC) is a well-known complication of HSCT. Its overall incidence has been reported to vary from 7-68%. The spectrum of clinical presentation varies from asymptomatic microhematuria to life-threatening bleeding. Sodium hyaluronate is a glycosaminoglycan present on the bladder mucosa, which serves as an important protective substance against uroepithelial damage. Preparations of this component have been shown to be effective in the treatment of interstitial cystitis. We report our experience in the treatment of post-transplant HC with intravesical instillation of sodium hyaluronate. Five out of the seven patients included in this study achieved complete response, while one patient had only partial response. Sodium hyaluronate administration was not associated with any local or systemic adverse effects. We consider that the results of our study are promising and the efficacy of sodium hyaluronate in the treatment of post-transplant HC should be tested in larger cohorts of patients.
Miodosky
M
M
Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
Abdul-Hai
A
A
Tsirigotis
P
P
Or
R
R
Bitan
M
M
Resnick
I B
IB
Gesundheit
B
B
Zilberman
I
I
Ioffe
L
L
Leubovic
A
A
Slavin
S
S
Shapira
M Y
MY
D000283:Administration, Intravesical; D000293:Adolescent; D000328:Adult; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006417:Hematuria / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008297:Male; D019172:Transplantation Conditioning / Q000009:adverse effects; D016896:Treatment Outcome
D006820:Hyaluronic Acid